All In Biotech

Drug Trial Radar · NCT06731764

Novel Approaches to the Treatment of Hypothyroidism

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Dec 10, 2024

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
UConn HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hypothyroidism is a common condition, more frequent in females, associated with excess of cardiovascular risk and poor quality of life not completely abrogated by treatment with levothyroxine. There is an unmet need to define a safe, effective, and feasible regimen to be applied in large trials aimed at assessing levothyroxine/liothyronine combination therapy in patients living with hypothyroidism. To address this knowledge gap we propose a randomized, three-arm, double-blind, controlled, escalating dose parallel pilot study whose results will lay the foundation of large multicenter trial(s) able to demonstrate the effectiveness (or lack thereof) of levothyroxine/liothyronine combination therapy.

Conditions

  • Hypothyroidism

Interventions

  • LevothyroxineDrug

    Patients will receive Levothyroxine/Placebo Levothyroxine/Liothyronine with Liothyronine administered twice daily.

  • Levothyroxine/Liothyronine once dailyDrug

    Patients will receive Levothyroxine/Liothyronine with Liothyronine administered once daily;

  • Levothyroxine/Liothyronine twice dailyDrug

    Patients will receive Levothyroxine/Liothyronine with Liothyronine administered twice daily;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in Total CholesterolTime frame: 6 month
  2. Changes in LDL CholesterolTime frame: 6 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UConn Health

    Farmington, Connecticut · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.